Tools for adapting cancer trials during the COVID-19 pandemic: an interview with Harish Dave

In this interview with Harish Dave (AUM Biosciences, Singapore) we explore how the COVID-19 pandemic has led to the adaptation of cancer clinical trials including how decentralizing clinical trials can expedite oncology research and drug development. We also speak about what's in store for the oncology industry against the COVID-19 backdrop. How can decentralizing clinical trials expedite oncology research and drug development? Over the past decade, the conventional centralized, “big pharma” innovation model has resulted in more than a 100% increase in the cost of developing new drugs, despite a 10 times reduction in the Internal Rate of Return (IRR)...